Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients | Zendy

Karin Neukam | Zendy; J Mira | Zendy; Josefa RuizMorales | Zendy; A. Rivero | Zendy; Antonio Collado | Zendy; Almudena Torres-Cornejo | Zendy; Dolores Merino | Zendy; Ignacio de los Santos | Zendy; Juan Macı́as | Zendy; Mercedes GonzálezSerrano | Zendy; Ángela Camacho | Zendy; Ginés David Parra-García | Zendy; Juan A. Pineda | Zendy; Antonio RiveroJuárez | Zendy; Inés PérezCamacho | Zendy; Julián TorreCisneros | Zendy; A. Aliaga-Jimenez | Zendy; Luís F. LópezCortés | Zendy; Rosario Palacios-Muñoz | Zendy; J. Santos-Gonzalez | Zendy; Manuel Márquez | Zendy; Enrique Nuño-Álvarez | Zendy; Antonio Fernández | Zendy

Open Access

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

Author(s) -

Karin Neukam,

J Mira,

Josefa RuizMorales,

A. Rivero,

Antonio Collado,

Almudena Torres-Cornejo,

Dolores Merino,

Ignacio de los Santos,

Juan Macı́as,

Mercedes GonzálezSerrano,

Ángela Camacho,

Ginés David Parra-García,

Juan A. Pineda,

Antonio RiveroJuárez,

Inés PérezCamacho,

Julián TorreCisneros,

A. Aliaga-Jimenez,

Luís F. LópezCortés,

Rosario Palacios-Muñoz,

J. Santos-Gonzalez,

Manuel Márquez,

Enrique Nuño-Álvarez,

Antonio Fernández

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr357

Subject(s) - efavirenz , ritonavir , medicine , gastroenterology , regimen , reverse transcriptase inhibitor , hepatitis c , hepatitis c virus , interquartile range , protease inhibitor (pharmacology) , adverse effect , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , virus

To compare the frequency of grade 3 or 4 transaminase elevations (TEs) in HIV/hepatitis C virus (HCV) co-infected patients who started a three-antiretroviral drug regimen including efavirenz or a ritonavir-boosted protease inhibitor (PI/r) and the influence of pre-existing significant hepatic fibrosis or cirrhosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research